Document is current

Any future updates will be listed below

229 Discovery of ganglioside GM2 activator as a novel proteomic biomarker associated with response to treatment in first-line melanoma subjects treated with PD-1 immunotherapy

Crossref DOI link: https://doi.org/10.1136/jitc-2020-SITC2020.0229

Published Online: 2020-11-09

Published Print: 2020-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

About CrossMark